TIBSOVO (ivosidenib tablets) was studied in a patient population reflective of that seen in clinical practice
| Selected baseline demographic and disease characteristics (N=174)1 | |
|---|---|
| Median age, years (min, max) | 67 (18, 87) |
| ECOG PS | |
| 0 | 36 (21) |
| 1 | 97 (56) |
| 2 | 39 (22) |
| 3 | 2 (1) |
| IDH1 mutation | |
| R132C | 102 (59) |
| R132H | 43 (25) |
| R132G | 12 (7) |
| R132S | 10 (6) |
| R132L | 7 (4) |
| Cytogenetic risk status | |
| Intermediate | 104 (60) |
| Poor | 47 (27) |
| Missing/unknown | 23 (13) |
| Relapse type | |
| Primary refractory | 64 (37) |
| Refractory relapse | 45 (26) |
| Untreated relapse | 65 (37) |
| Prior stem cell transplantation for AML | 40 (23) |
| Transfusion dependent at baselinea | 110 (63) |
| Type of AML | |
| De novo AML | 116 (67) |
| Secondary AML | 58 (33) |
aPatients were defined as transfusion dependent at baseline if they received any RBC or platelet transfusion occurring within 56 days prior to the first dose of TIBSOVO.1
Many patients in the study had challenging disease characteristics
59% of patients had ≥2 prior anticancer therapies2
-
Median number of prior therapies (min, max): 2 (1, 6)1
33% of patients had secondary AML1
23% of patients had prior stem cell transplantation for AML1
87% of patients had intermediate or poor cytogenic risk status1
Study design
TIBSOVO® was studied as a single agent in both the newly diagnosed and R/R AML settings1
TIBSOVO is a first-in-class agent that inhibits the mutant IDH1 enzyme to induce myeloid differentiation1
-
The pivotal trial for TIBSOVO monotherapy was an open-label, single-arm, multicenter trial1
-
IDH1 mutations were identified by a local or central diagnostic test and confirmed retrospectively using the Abbott RealTime IDH1 assay, which is the FDA-approved test for selection of patients with AML for treatment with TIBSOVO1
Patients were assigned a starting dose of TIBSOVO 500 mg daily and received treatment until disease progression, development of unacceptable toxicity, or undergoing hematopoietic stem cell transplantation1
-
Safety and efficacy were evaluated in 28 IC-ineligible patients with newly diagnosed AML1
-
Safety was evaluated in 179 patients and efficacy was evaluated in 174 patients with R/R AML1
Efficacy was established based on the rate of CR and/or CRh, duration of CR+CRh, as well as the rate of conversion from transfusion dependence to transfusion independence1,a
aCR was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, full recovery of peripheral blood counts (absolute neutrophil count >1000/μL and platelets >100,000/μL), and independence of red blood cell transfusions.2 CRh was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, and partial recovery of peripheral blood counts (absolute neutrophil count >500/μL and platelets >50,000/μL).1
AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematological recovery; IC, induction chemotherapy; IDH1, isocitrate dehydrogenase-1; R/R, relapsed or refractory.
AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IDH1, isocitrate dehydrogenase‑1; RBC, red blood cell.
59% of patients had ≥2 prior anticancer therapies2
- Median number of prior therapies (min, max): 2 (1, 6)1
33% of patients had secondary AML1
23% of patients had prior stem cell transplantation for AML1
87% of patients had intermediate or poor cytogenic risk status1
Study design
TIBSOVO® was studied as a single agent in both the newly diagnosed and R/R AML settings1
TIBSOVO is a first-in-class agent that inhibits the mutant IDH1 enzyme to induce myeloid differentiation1
- The pivotal trial for TIBSOVO monotherapy was an open-label, single-arm, multicenter trial1
- IDH1 mutations were identified by a local or central diagnostic test and confirmed retrospectively using the Abbott RealTime IDH1 assay, which is the FDA-approved test for selection of patients with AML for treatment with TIBSOVO1
- Safety and efficacy were evaluated in 28 IC-ineligible patients with newly diagnosed AML1
- Safety was evaluated in 179 patients and efficacy was evaluated in 174 patients with R/R AML1
Efficacy was established based on the rate of CR and/or CRh, duration of CR+CRh, as well as the rate of conversion from transfusion dependence to transfusion independence1,a
AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IDH1, isocitrate dehydrogenase‑1; RBC, red blood cell.
TIBSOVO delivered deep responses as a once-daily oral treatment in a difficult-to-treat disease
- CR+CRh rate appeared to be consistent across all baseline demographics and baseline disease characteristics with the exception of number of prior regimens1
bCR was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, full recovery of peripheral blood counts (absolute neutrophil count >1000/μL and platelets >100,000/μL), and independence of red blood cell transfusions.1,2 CRh was defined as <5% blasts in the bone marrow and no Auer rods, absence of extramedullary disease, and partial recovery of peripheral blood counts (absolute neutrophil count >500/μL and platelets >50,000/μL).
Patients achieved CR or CRh after receiving 1 or more prior regimens2
47% of R/R patients who had received 1 prior regimen (35/74) achieved CR or CRh (95% CI, 35.6‑59.3)2
30% of R/R patients who had received 2 prior regimens (15/50) achieved CR or CRh (95% CI, 17.9‑44.6)2
15% of R/R patients who had received ≥3 prior regimens (7/48) achieved CR or CRh (95% CI, 6.1-27.8)2
AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematological recovery; R/R, relapsed/refractory.
TIBSOVO provided durable responses1
Median duration of response1,c
Description
Horizontal bar chart presenting median duration of response in patients treated with TIBSOVO, reported for complete remission (CR) and composite remission (CR+CRh).
Median duration of response was 10.1 months (95% CI, 6.5–22.2) in patients achieving CR (n=43) and 8.2 months (95% CI, 5.6–12) in patients achieving CR+CRh (n=57).
cDuration of CR and CR+CRh were defined as time since first response of CR or CR/CRh, respectively, to relapse or death, whichever was earlier.1
- Median treatment duration: 4.1 months (range, 0.1-39.5)1
- Some patients experienced long treatment durations of over 3 years with TIBSOVO (range, 0.2-39.5 months)1
- Median follow-up: 8.3 months (range, 0.2-39.5)1
CR, complete remission; CRh, complete remission with partial hematological recovery.
TIBSOVO enabled strong and rapid responses1,3
Time to response with TIBSOVO
CR, complete remission; CRh, complete remission with partial hematological recovery.
Transfusion independence was seen in 37% of transfusion-dependent patients who received TIBSOVO1
Patients were defined as transfusion dependent at baseline if they received any RBC or platelet transfusions within 56 days prior to the first dose of TIBSOVO. Patients were defined as transfusion independent if they became independent of transfusions during any 56-consecutive-day postbaseline period.1
RBC, red blood cell.
TIBSOVO improved hematologic parameters3
TIBSOVO demonstrated an improvement in hematologic variables together with a reduction in bone marrow blasts
Increase in mean platelet count and mean absolute neutrophil counts
Description
Line graph presenting the increase in mean platelet count (109/L, left y-axis) and mean absolute neutrophil count (109/L, right y-axis) in patients treated with TIBSOVO monotherapy, measured at each cycle from Cycle 0 through Cycle 12. Error bars are displayed at each timepoint.
Mean platelet counts rise from baseline through Cycle 2, decline through Cycle 3, then increase gradually through Cycle 9, after which values stabilize through Cycle 12. Mean absolute neutrophil counts remain low at baseline, then rise from Cycle 1 onward, increasing gradually through Cycle 12.
Increase in mean hemoglobin level, decrease in mean bone marrow blasts
Description
Line graph presenting the increase in mean hemoglobin level (g/L, left y-axis) and decrease in mean bone marrow blasts (%, right y-axis) in patients treated with TIBSOVO monotherapy, measured at each cycle from Cycle 0 through Cycle 12. Error bars are displayed at each timepoint. The number of patients evaluated at each cycle is noted below the x-axis for both hemoglobin and bone marrow blasts.
Mean hemoglobin levels remain relatively stable from baseline through Cycle 3, then increase gradually through Cycle 12. Mean bone marrow blast percentage declines from baseline through Cycle 4, after which values stabilize and remain relatively consistent through Cycle 12.
Adapted with permission from DiNardo et al.
Data are mean values with standard deviations.